AbbVie (ABBV) Surged Following Strong Results and Increased Guidance

4 days ago 2

Soumya Eswaran

Wed, November 12, 2025 astatine 8:18 AM CST 2 min read

Carillon Tower Advisers, an concern absorption company, released its “Carillon Eagle Growth & Income Fund” third-quarter 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. The S&P 500 Index continued its rally successful the 3rd quarter, ending the year-to-date returns astatine 13.7%. During this period, maturation and momentum were cardinal contributors to the market's performance. A important information of the marketplace is presently tied to the azygous catalyst of AI deployment, which means that immoderate weaknesses successful this conception could importantly endanger the market's aboriginal strength. In addition, delight cheque the fund’s apical 5 holdings to cognize its champion picks successful 2025.

In its third-quarter 2025 capitalist letter, Carillon Eagle Growth & Income Fund highlighted stocks specified arsenic AbbVie Inc. (NYSE:ABBV). AbbVie Inc. (NYSE:ABBV) is simply a research-based biopharmaceutical company. The one-month instrumentality of AbbVie Inc. (NYSE:ABBV) was -0.46%, and its shares gained 32.18% of their worth implicit the past 52 weeks. On November 11, 2025, AbbVie Inc. (NYSE:ABBV) banal closed astatine $225.17 per share, with a marketplace capitalization of $397.962 billion.

Carillon Eagle Growth & Income Fund stated the pursuing regarding AbbVie Inc. (NYSE:ABBV) successful its 3rd 4th 2025 capitalist letter:

"AbbVie Inc. (NYSE:ABBV) issued a beardown second-quarter fiscal update that included accrued 2025 guidance. The institution besides announced a ineligible colony with generic competitors that volition effect successful 3 further years of patent extortion for 1 of its largest, and fastest- increasing products."

AbbVie Inc. (NYSE:ABBV) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. According to our database, 89 hedge money portfolios held AbbVie Inc. (NYSE:ABBV) astatine the extremity of the 2nd quarter, up from 86 successful the erstwhile quarter. AbbVie Inc. (NYSE: ABBV) reported full net revenues of astir $15.8 cardinal successful Q3 2025, exceeding expectations by astir $300 million. While we admit the imaginable of AbbVie Inc. (NYSE:ABBV) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

In another article, we covered AbbVie Inc. (NYSE:ABBV) and shared the database of champion DRIP stocks to own. In addition, delight cheque retired our hedge money capitalist letters Q3 2025 page for much capitalist letters from hedge funds and different starring investors.